Ocular Therapeutix Shares Are Trading Lower. The Company Announced Topline Results From the Phase 1 HELIOS Study Evaluating AXPAXLI in Patients With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Ocular Therapeutix的股价正在走低。该公司公布了评估中重度至重度非增殖性糖尿病视网膜病变患者AXPAXLI的1期HELIOS研究的主要结果